Today: 15 May 2026
Deere Stock Tumbles Before Earnings as Wall Street Tests John Deere’s 2026 Rebound
25 April 2026
2 mins read

Deere Stock Tumbles Before Earnings as Wall Street Tests John Deere’s 2026 Rebound

MOLINE, Illinois, April 25, 2026, 10:02 CDT

Deere & Company shares dropped 4.95% to $562.64 on Friday, shaving $29.31 off the stock’s value and casting a shadow over the John Deere 2026 rebound narrative, with fiscal second-quarter earnings due in under a month. Roughly 1.1 million shares changed hands, according to the company’s investor site.

This comes into sharper focus with Deere approaching its May 21 earnings update—investors are already juggling questions about sluggish demand for big farm equipment and management’s suggestion that the cycle’s worst point could be close. Analysts are calling for quarterly EPS at $5.81, which would mark a 12.5% drop from the previous year, according to Barchart on Friday.

Looking ahead to fiscal 2026, Wall Street’s consensus sits at $18.01 in Deere EPS, about 2.7% lower than the previous year. They’re penciling in a recovery to $23.01 for fiscal 2027. That doesn’t leave much of a buffer: Deere shares still reflect hopes for steady farm-equipment demand holding up until profits bounce back.

Deere trailed its main rivals on Friday. According to MarketWatch, Caterpillar slipped 0.53%, CNH Industrial was down 2.38%, and Deere took the biggest hit, falling 4.95%. On the broader front, Barchart data had the S&P 500 up 0.80%, while the Industrial Select Sector SPDR Fund slid 0.92%.

Deere’s shares slid even after the company lifted its fiscal 2026 net income outlook back in February to between $4.5 billion and $5.0 billion. For the first quarter, Deere posted net income of $656 million, or $2.42 per share. Sales and revenue globally climbed 13%, coming in at $9.61 billion. At the time, CEO John May called 2026 “the bottom of the current cycle.” John Deere

The low point isn’t exactly clear-cut. Deere flagged ongoing pressure in large ag, though construction equipment and smaller ag markets are picking up. Back in February, Reuters noted Deere cut factory production in response to softer demand, while Oppenheimer’s Kristen Owen pointed out that depleted inventories could set the stage for gains as supplies return to normal.

The risk hasn’t gone away. Deere is bracing for an estimated $1.2 billion pre-tax tariff impact in fiscal 2026, according to Reuters. This year, the USDA projects U.S. net farm income at $153.4 billion, down 0.7%. With crop prices weaker and input costs stubbornly high, farmers may hold off on buying big-ticket equipment like tractors or combines.

Wall Street’s sticking with the stock for now. According to MarketBeat on Saturday, 16 analysts still say Buy on Deere, nine call it Hold, and the average price target sits at $655.45. DA Davidson, Wolfe Research, and Bank of America have all bumped up their targets lately, the same report noted.

Legal uncertainty hangs over as well. Deere announced on April 6 that it had settled multidistrict “right to repair” litigation—no admission of wrongdoing, according to the company. Deere has committed to continue granting access to tools, manuals, and diagnostic software. The deal is still subject to court approval. John Deere

Denver Caldwell, who heads aftermarket and customer support at Deere, said the company is still committed to providing customers and service shops with “access to repair resources.” Repair costs and software access have turned into bigger headaches for farmers, Caldwell said, as equipment increasingly relies on sensors, digital tools, and diagnostics tied to dealers. John Deere

Deere’s current position leaves little room. If May’s numbers come in strong, that backs up management’s stance on being at the cycle’s trough. But a disappointing report, and doubts resurface about whether construction and smaller ag can really make up for sluggish big-farm demand, tariffs, and buyers still wary of shelling out for high-priced new machines.

Stock Market Today

  • The $410 Billion AI IPO Boom Set to Reshape Market Indexes
    May 15, 2026, 10:36 AM EDT. The surge in artificial intelligence (AI) initial public offerings (IPOs) is on track to generate $410 billion in trade, potentially reshuffling major stock market indexes. This wave of IPOs reflects investor appetite for AI-driven companies poised for growth. Market participants anticipate significant changes in index compositions as these new listings gain prominence. The evolving landscape underscores AI's increasing role in capital markets, influencing stock valuations and investor strategies amid this transformative boom.

Latest articles

Plug Power Stock Drops Again: The $5 Billion Hydrogen Turnaround Faces Its Cash Test

Plug Power Stock Drops Again: The $5 Billion Hydrogen Turnaround Faces Its Cash Test

15 May 2026
New York, May 15, 2026, 10:10 EDT Plug Power Inc. shares slipped in early Nasdaq trading on Friday, trimming more of a sharp post-earnings move as investors weighed stronger first-quarter sales against the hydrogen company’s still-heavy cash use. The stock was recently at $3.725, down about 1.7%, leaving the company with a market value of about $5.2 billion. The move matters because the rally had come fast. Plug jumped 11.24% on Wednesday, then fell 4.29% on Thursday, snapping a three-day winning streak even as broader U.S. indexes rose. That leaves the market with a cleaner question than usual: whether Plug’s
Why Ford Motor Company Stock Is Sliding After Its AI Data Center Rally

Why Ford Motor Company Stock Is Sliding After Its AI Data Center Rally

15 May 2026
Ford shares dropped 7% to $13.43 in early Friday trading, reversing part of a rally sparked by the launch of its new Ford Energy unit. The subsidiary, announced this week, will sell large battery energy storage systems to utilities and data centers, with first deliveries expected in late 2027. CEO Jim Farley said Ford is in the contracting phase with several customers. The stock had surged 13% Wednesday after Morgan Stanley highlighted the business.
Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

15 May 2026
Biogen has closed its acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and delisting its shares from Nasdaq. Apellis shareholders receive $41 per share in cash plus a contingent value right tied to Syfovre sales. Biogen gains the drugs Empaveli and Syfovre, and expands into kidney disease. Biogen borrowed $2 billion to help finance the deal.
Nokia Oyj Stock Pulls Back After AI Rally: What Investors Need to Know

Nokia Oyj Stock Pulls Back After AI Rally: What Investors Need to Know

15 May 2026
Nokia’s U.S.-listed shares dropped about 5% Friday, trading at $13.74 after a recent AI-driven surge. The decline followed a rally sparked by Cisco’s report of $5.3 billion in AI infrastructure orders from hyperscalers. Nokia saw a 54% jump in first-quarter operating profit and named Siemens’ Emma Falck as president of Mobile Infrastructure, effective September 1.
The Trade Desk Stock Just Got a Short-Squeeze Signal. Earnings Could Decide the Next Move
Previous Story

The Trade Desk Stock Just Got a Short-Squeeze Signal. Earnings Could Decide the Next Move

Rivian’s R2 Moment Is Here, and Traders Are Betting the Next Move Could Be Sharp
Next Story

Rivian’s R2 Moment Is Here, and Traders Are Betting the Next Move Could Be Sharp

Go toTop